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OBJECTIVE—Insulin resistance in skeletal muscle is an early
phenomenon in the pathogenesis of type 2 diabetes. Studies of
insulin resistance usually are highly focused. However, ap-
proaches that give a more global picture of abnormalities in
insulin resistance are useful in pointing out new directions for
research. In previous studies, gene expression analyses show a
coordinated pattern of reduction in nuclear-encoded mitochon-
drial gene expression in insulin resistance. However, changes in
mRNA levels may not predict changes in protein abundance. An
approach to identify global protein abundance changes involving
the use of proteomics was used here.
RESEARCH DESIGN AND METHODS—Muscle biopsies were
obtained basally from lean, obese, and type 2 diabetic volunteers
(n  8 each); glucose clamps were used to assess insulin
sensitivity. Muscle protein was subjected to mass spectrometry–
based quantification using normalized spectral abundance
factors.
RESULTS—Of 1,218 proteins assigned, 400 were present in at
least half of all subjects. Of these, 92 were altered by a factor of
2 in insulin resistance, and of those, 15 were significantly
increased or decreased by ANOVA (P 0.05). Analysis of protein
sets revealed patterns of decreased abundance in mitochondrial
proteins and altered abundance of proteins involved with cy-
toskeletal structure (desmin and alpha actinin-2 both decreased),
chaperone function (TCP-1 subunits increased), and proteasome
subunits (increased).
CONCLUSIONS—The results confirm the reduction in mito-
chondrial proteins in insulin-resistant muscle and suggest that
changes in muscle structure, protein degradation, and folding
also characterize insulin resistance. Diabetes 59:33–42, 2010
Skeletal muscle insulin resistance is critical to thepathogenesis of type 2 diabetes (1) and the met-abolic syndrome (2). Numerous investigationsover the past 4 decades have revealed an array of
abnormalities in insulin action in skeletal muscle of obese
and type 2 diabetic patients and have led to a better
understanding of the molecular pathways involved in
insulin and cytokine signaling, inflammation, and gene
expression in skeletal muscle. In insulin-resistant muscle,
there are defects in insulin signaling (3,4), activities of
metabolic enzymes (5,6), and regulation of gene expres-
sion (6–9), among others.
Often these studies are highly focused. However, several
groups have used approaches that give a more global
picture of abnormalities, such as oligonucleotide microar-
ray analysis (7–9). The value of global analysis is that it can
yield a view of patterns of changes in pathways and
generate new hypotheses that serve as foci for more
detailed analysis. Global gene expression analyses con-
ducted in insulin-resistant muscle have shown a pattern of
reduced expression of nuclear-encoded mitochondrial
genes (7–9). Such findings have spurred new avenues of
research and fit well with observations of mitochondrial
dysfunction in insulin resistance (10).
However, changes in mRNA levels for a gene may not be
mirrored by changes in abundance of the proteins encoded
by that gene, which are a closer reflection of the level of
activity of a biological pathway. The advent of sensitive
and accurate mass spectrometers has made mass spec-
trometry a valuable tool for biologists interested in protein
identification and regulation of protein abundance in com-
plex biological mixtures. Mass spectrometry–based pro-
teomics also is a valuable tool for quantifying differences
in protein abundance between, for example, cells cultured
in vitro under different conditions or treatments (11–14).
Assessment of differences in protein abundance using
mass spectrometry analysis of human tissues, where in
vivo stable isotope labeling of proteins is impractical,
presents special challenges (15–18).
The challenge of comparative proteomics in small hu-
man tissue samples has resulted so far in studies that have
revealed only a few differences in protein abundance in
insulin-resistant muscle (18–20). These challenges were
addressed here through the use of an initial separation
technique of one-dimensional SDS-polyacrylamide gels,
with protein assignment using high-performance liquid
chromatography–electrospray ionization–tandem mass
spectrometry (HPLC-ESI-MS/MS) and with quantification
using a normalized spectral abundance factor (NSAF)
method (21–23). The purpose of this study was to develop
a global view of protein abundance changes in insulin
resistance, in order to provide data that can serve as a
basis for generation of novel hypotheses concerning the
molecular mechanisms of insulin resistance. Using these
techniques, we assigned a total of 1,218 proteins in small
percutaneous muscle biopsies taken from metabolically
characterized lean and obese nondiabetic volunteers and
type 2 diabetic patients. We used normalized spectral
abundance factor methods to compare the abundance of
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400 of the proteins that were assigned in at least half of all
subjects studied. These analyses reveal unexpected new
patterns of changes in protein abundance in insulin-
resistant muscle, including alterations in abundance of
proteins involved in cytoskeletal structure and assembly
and increases in proteasome and chaperone subunit
abundance.
RESEARCH DESIGN AND METHODS
Lean nondiabetic control subjects, obese nondiabetic subjects, and patients
with type 2 diabetes (n  8 each) were studied. Studies were approved by the
Institutional Review Board of the University of Texas Health Science Center
at San Antonio and Arizona State University. After giving informed written
consent, each volunteer underwent a medical history, physical examination,
screening laboratory tests, and a 75-g oral glucose tolerance test and under-
went a euglycemic-hyperinsulinemic clamp with basal muscle biopsies as
described (3,24,25). Complete details are provided in the online appendix,
which is available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0214/DC1.
Gel electrophoresis and mass spectrometry analysis. Muscle lysate
proteins (60 g total protein) were separated on 4–20% linear gradient SDS
polyacrylamide gels and processed for mass spectrometry as described
(26,27) and as outlined in supplemental Fig. 1 in the online appendix. A
complete description of this analysis is provided in the online appendix.
Normalized spectral abundance factors. To quantify protein abundance,
NSAFs were used (21–23). Tandem mass spectrometry (MS/MS) spectra
assigned to a protein were normalized to the length of the protein (number of
amino acids), resulting in a spectral abundance factor (SAF), where SAF 
spectrum count/number AA. Each SAF was normalized against the sum of all
SAFs in one sample, resulting in the NSAF value. For a protein, i, the
normalized spectral abundance factor, NSAF, is calculated by
NSAFi  SAFi/i  1
N
SAFi
where N is the total number of proteins detected in a sample. Thus, NSAF
values allow for direct comparison of a protein’s abundance between individ-
ual runs in a fashion similar to microarray data analysis.
Reproducibility and linearity of NSAF method. To determine linearity,
varying amounts of BSA tryptic digests (62–250 fmol) were added to 125 fmol
cytochrome c digest. Mixtures were analyzed by MS/MS. To assess linearity
in a “real life” complex mixture of proteins, muscle biopsy lysates were
used. If NSAF provides an accurate reflection of the proportion of any
particular protein in a complex protein sample, such as a muscle lysate,
then the NSAF for any given protein should be equivalent, no matter how
much total protein is analyzed. Complete methods for testing this and a
description of the reproducibility experiment are described in the online
appendix.
Single protein analysis. Although a large number of proteins were assigned
in at least one of 24 subjects who were studied, a series of filters were used
to narrow the number of proteins that were used in comparisons among
groups. This approach is diagrammed in Fig. 1, with complete details provided
in the online appendix.
Differential patterns of protein abundance among groups (protein
sets). Differences in NSAF values for a set of proteins among groups were
assessed as diagrammed in Fig. 2, with a complete description provided in the
online appendix.
To better visualize patterns of differences among groups, protein
abundance changes were visualized using the Gene Expression Dynamics
Inspector (GEDI) (http://www.childrenshospital.org/research/ingber/GEDI/
gedihome.htm) (28). GEDI uses an algorithm that groups individual proteins
by patterns of group differences compared with an overall median. Proteins
for a particular grouping that are generally lower in abundance than the global
mean are depicted in shades of blue, whereas proteins that are increased are
depicted in shades of orange and red, similar to a heat map.
Immunoblot analysis. To determine the relationship between NSAF quanti-
fication and relative protein abundance determined by immunoblot analysis,
two proteins (desmin and alpha actinin-2) that differed significantly among the
groups by NSAF analysis were subjected to immunoblot analysis. Only seven
of the eight subjects in each group had sufficient muscle protein remaining to
perform these analyses. Muscle protein lysates were resolved by SDS-PAGE,
transferred to nitrocellulose membranes, and probed using antibodies against
alpha actinin-2 or desmin (both from Santa Cruz Biotechnology, Santa Cruz,
CA). PDLIM6 protein was used as a loading control (antibody from Santa Cruz
Biotechnology). Blots were quantified by densitometry (VersaDoc 5000;
Bio-Rad Laboratories, Hercules, CA).
RESULTS
Clinical and metabolic characteristics. The diabetic
subjects had greater fasting plasma glucose and A1C than
the obese or lean control subjects (P  0.01) (Table 1).
Obese (P  0.01) and diabetic (P  0.05) subjects had a
greater BMI. The diabetic subjects were slightly older than
the lean group (48  3 vs. 37  4 years, P 0.05), although
the average age of the obese group was intermediate and
did not differ significantly from either of the other groups.
As expected, the rate of insulin-stimulated glucose uptake
was significantly impaired in the obese nondiabetic group
and further decreased in the diabetic subjects.
Linearity and reproducibility of NSAF technique. The
relationship between the proportion of BSA spectra in a
mixture of BSA and cytochrome c and BSA concentration fit
a linear regression (r2  0.90, y  3.23x  0.19). Using a
complex mixture of proteins (muscle lysate) over a fourfold
concentration range (30–120 g protein), there was a linear
relationship between NSAF values. The regression equations
for these three comparisons (30 vs. 60, 30 vs. 120, and 60 vs.
120 g protein) were y  0.61  0.05, y  1.21x  2.49, and
y 1.99x 2.67, with r2  0.99, 0.94, and 0.96, respectively.
Figure 3 shows the relationship between NSAF values ob-
tained with 30 and 120 g protein.
To assess reproducibility, three separate portions of a
muscle biopsy from a single individual were individually
homogenized, run in separate lanes on an SDS gel, and the
gel slices trypsinized and processed for high-performance
liquid chromatography electrospray ionization–tandem
mass spectrometry as described above (20 slices per lane).
A total of 334 proteins were assigned that were common to
all three biopsy portions, and the average coefficient of
variation for these proteins was 22.1%. Power analysis
(NQuery Advisor; Statistical Solutions, Saugus, MA) re-
vealed that, using a coefficient of variation of 22.1%, an
ANOVA with eight subjects per group has a power of90%
to detect a difference of twofold at the 0.05 level.
Muscle proteome. When the results from all 24 volun-
teers were combined and redundant results were col-
lapsed, 1,218 proteins were assigned in at least one of the
24 subjects. The complete list of proteins that were
assigned is provided as supplemental Table 1, which is
available in the online appendix. Proteins that were as-
signed in at least half (12 of 24) of all participants totaled
400 and are listed in supplemental Table 2. This set of 400
proteins was used for further analysis.
Single protein analysis. Out of 400 proteins that were
assigned as present in at least 12 of 24 subjects, a total of
92 of these proteins also were increased or decreased by a
factor of two in at least one of the three possible two-
group comparisons (obese versus lean, diabetic versus
lean, or diabetic versus obese) and are given in supple-
mental Table 3. Of these 92 proteins, 15 were significantly
different among the three groups using one-way ANOVA
(P 0.05, Table 2). Because variances for NSAFs for about
half the proteins analyzed were not homogeneous, we also
used the nonparametric Kruskal-Wallis test to analyze
these data. Of the 15 proteins that significantly differed by
ANOVA, 10 also significantly differed by Kruskal-Wallis,
and of the other five proteins, two had P values 0.10 and
three had P values 0.17.
Of the 15 proteins that differed significantly by ANOVA
among the groups, 9 were greater in abundance and 6 were
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lower in insulin resistance. Of the six that were lower,
three were mitochondrial in location, cytochrome C oxi-
dase VIC precursor (gene name COX6C), coiled-coil-helix-
coiled-coil-helix domain-containing protein 3 (gene name
CHCHD3), and ubiquinol-cytochrome C reductase com-
plex ubiquinone-binding protein QP-C (gene name
UQCRQ), while none of the nine proteins that increased
were mitochondrial. Average NSAF values for these
proteins are shown in Fig. 4A. The proportion of mito-
chondrial proteins in the proteins that decreased (3 of 6)
was significantly greater than that in proteins that
increased in abundance (0 of 9) (P  0.05, Fisher exact
probability test). Three nonmitochondrial proteins that
were significantly higher in insulin resistance were
proteins that are components of the cytoskeleton or
structure of myocytes (alpha actinin 2, myozenin-1, and
desmin; Fig. 4B).
This same pattern of decreased mitochondrial proteins
also was present in the 77 proteins that differed by a factor
of two but were not significant by ANOVA (supplemental
Table 3). The P values determined using both ANOVA and
Kruskal-Wallis are shown in this table also. The correla-
tion between P values for the two methods was 0.76 (P 
0.01). Of those 77 proteins, 19 were lower in abundance in
obese versus lean, diabetic versus lean, or diabetic versus
obese subjects, and 58 were greater in abundance by a
factor of 2 in either obese or diabetic subjects versus
lean control subjects. Of the 19 that were lower in
abundance in insulin resistance, 9 were mitochondrial;
of the 58 that were higher in abundance, only 3 were
Proteins assigned with 99%
confidence in at least one subject?
(1218 proteins - Supplemental Table 1)
NSAF values determined
Protein assigned in at least 12 of 24 (half) of subjects?
No
(no further analysis)
Yes
(400 proteins - Supplemental Table 2)
Mean NSAF altered by factor of 2
between at least 2 of the 3 groups?
Yes
(92 proteins) No(no further analysis)
Significant (P<0.05) by ANOVA?
(also perform Kruskal-Wallis test)
No
(77 proteins - Supplemental Table 3)
Yes
(15 proteins - Table 2)
FIG. 1. Work flow of statistical analysis of single proteins.
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mitochondrial (P  0.002, Fisher exact probability test),
including citrate synthase. Among the mitochondrial
proteins that decreased by a factor of 2 but were not
Combine into sets based on
GO classifications or
manually curation
Proteins assigned with 99%
confidence in at least half
(12 of 24 subjects)?
Compute normalized average
NSAF value for all proteins
in a set for each individual
in the three groups
Significant by analysis
of variance (P < 0.05)?
No
(no further analysis)
Yes
21 sets (Supplemental Table 4)
FIG. 2. Work flow of statistical analysis of protein sets.
TABLE 1
Subject characteristics
Lean Obese Diabetic
n 8 8 8
Sex (F/M) 4/4 4/4 4/4
Age (years) 37  4 44  3 48  3*
BMI (kg/m2) 24.3  0.8 31.6  0.8† 29.0  1.1*
Body fat (%) 26.8  2.9 33.7  2.8 34.2  3.5
M mg/(kg  min) 8.2  0.7 3.8  0.2† 1.6  0.5†
Fasting blood glucose
(mg/dl) 94  5 97  1 148  25†
A1C (%) 4.8  0.2 5.1  0.2 8.3  1.1†
Insulin (U/ml) 4.9  0.4 12.6  3.4† 9.7  2.9
Data are means  SE. *P  0.05, †P  0.01 vs. lean control subjects.
M, rate of glucose metabolism.
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FIG. 3. Linearity of the relationships between spectral abundance
factors observed when 30 and 120 g protein were analyzed, as
described in RESEARCH DESIGN AND METHODS. Similar data obtained for 30
vs. 60 and 60 vs. 120 g protein loading were compared (data not
shown).
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statistically significant by ANOVA were five additional
subunits involved in the electron transport chain, in-
cluding the ATP synthase 	-subunit, and two additional
proteins involved in import of proteins into mitochon-
dria, mitochondrial import inner membrane translocase
subunit TIM13, and sorting and assembly machinery
component homolog SAM50.
Regarding proteins that were increased in insulin resis-
tance, nine proteins were greater by at least twofold (obese
versus lean and/or diabetic versus lean) and also were
significant by ANOVA. Of those nine, three were chaperones
or co-chaperones (HSP90 co-chaperone CDC37, T-complex
protein 1 
 (TCP1 
), and T-complex protein 1  (TCP1 ).
HSP90 co-chaperone CDC37 was increased by a factor of
four- to eightfold in insulin resistant muscle, while the TCP1
subunits both were increased two- to threefold (Fig. 4C).
Two proteins that significantly increased are involved in
protein ubiquitination and degradation (cullin homolog 5
and proteasome subunit beta type 3). One protein, myosin-
15, is a molecular motor that was increased four- to
eightfold in insulin resistance. Another protein, protein
disulfide isomerase a3, which stabilizes proteins with
disulfide bonds, was increased two- to fourfold in insulin
resistance. Of note is NG,NG-dimethylarginine dimethyl-
aminohydrolase 1, which was higher by fourfold in obesity
and nearly threefold in the diabetic group.
Among the 77 proteins that were altered by a factor of 2
in insulin-resistant subjects but that were not statistically
significantly different, 58 were greater in abundance in
either obese or diabetic, or both, versus lean control
subjects. The 58 that were greater included a number of
proteins related to those that did increase significantly by
ANOVA. Perhaps the most pronounced example of this is
the TCP1 proteins, of which TCP1  and  subunits were
increased by twofold or more. NSAF values for the TCP1
subunits that were assigned in at least half the subjects are
given in Fig. 4C. In addition a number of proteasome
subunits also were higher by at least twofold in insulin
resistance, including 26S proteasome regulatory subunit 3,
26S proteasome regulatory subunit 4, proteasome subunit
beta type 4, proteasome 26S subunit 11 variant, isoform 1
of proteasome subunit alpha type 7, and 26S proteasome
regulatory subunit 7. NSAF values for the proteasome
subunits are shown in Fig. 4D. Other proteins, related to
the cytoskeleton or cell structure that were at least
twofold greater but were not significant by ANOVA, in-
cluded actin, alpha actinin-3, kinesin, and troponin.
Protein set analysis. Patterns of changes in proteins
were analyzed by comparing differences in abundance of
sets of proteins included in various gene ontology (GO)
classifications and selected hand-curated sets (electron
transport chain complexes I–V and TCP1 subunits). Only
sets containing five or more proteins were analyzed to
avoid undue influence of changes in only one or two
proteins in a set. Supplemental Table 4 shows representa-
tive sets that were significantly different (P  0.05 by
TABLE 2
Proteins differing significantly among groups
Protein name NSAF
Number of subjects
with protein assigned
Total spectra per
group
Lean Obese Diabetic PANOVA PK-W Lean Obese Diabetic Lean Obese Diabetic
HSP90 co-chaperone CDC37 0.22  0.22 1.92  0.50† 0.99  0.41 0.02‡ 0.03 1 6 5 3 18 11
Myosin-15 0.10  0.1 0.83  0.21* 0.54  0.22* 0.03 0.03 1 6 5 5 40 27
55-kDa protein; protein
disulfide-isomerase A3
precursor 0.29  0.21 1.71  0.61* 0.66  0.13 0.04‡ 0.05 2 6 7 4 22 9
Cullin homolog 5 0.17  0.08 0.78  0.21 0.87  0.28 0.05‡ 0.08 3 6 5 4 17 18
NG,NG-dimethylarginine
dimethylaminohydrolase 1 0.80  0.55 3.28  0.58* 2.32  0.63 0.02 0.03 2 8 6 6 24 17
Chaperonin containing TCP1,
subunit 8 (theta) variant;
T-complex protein 1
subunit theta 0.78  0.19 1.88  0.51 2.50  0.52* 0.03‡ 0.04 7 7 8 13 27 35
T-complex protein 1 subunit
delta 0.85  0.16 1.95  0.39* 2.00  0.34* 0.03 0.02 7 7 8 13 27 28
Glutaminyl-TRNA synthetase 0.32  0.16 0.60  0.20 1.30  0.42* 0.05 0.17 3 5 5 7 12 27
Proteasome subunit beta
type 3 0.78  0.32 0.92  0.37 2.05  0.55* 0.01 0.16 4 4 6 5 5 11
Alpha actinin-2 18.2  3.3 10.6  3.2* 8.18  1.22* 0.04‡ 0.05 8 8 8 508 282 195
Cytochrome C oxidase
polypeptide VIC precursor 72.1  15.1 38.2  10.6* 27.1  5.9* 0.03‡ 0.10 7 8 7 166 74 57
Coiled-coil-helix-coiled-coil-
helix domain-containing
protein 3 5.57  1.25 2.51  0.56* 2.07  0.91 0.03 0.03 8 7 4 36 15 12
Myozenin-1 6.65  1.73 2.70  1.78* 1.56  0.59 0.05‡ 0.13 6 2 5 68 27 13
Desmin; mutant desmin 3.98  0.96 1.45  0.52* 1.86  0.56* 0.04 0.07 7 5 6 62 21 24
Ubiquinol-cytochrome C
reductase complex
ubiquinone-binding
protein QP-C 21.4  5.70 4.03  2.70† 4.81  2.10† 0.006* 0.04 6 2 4 57 12 11
Data are for NSAF values  10,000 and are means  SE. P value listed is for overall ANOVA (PANOVA) and Kruskal-Wallis test (PK-W) among
groups. Total spectra  sum of spectra across eight subjects in each group. Individual group a posteriori comparisons: *P  0.05, †P  0.01
vs. lean control subjects, by a posteriori tests after ANOVA. ‡Variances not homogeneous.
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ANOVA) between obese and lean or diabetic and lean
subjects. GO classifications involving mitochondrial com-
partments or functions, such as electron transport, were
significantly lower in abundance in obese and diabetic
muscle. GO classifications where protein abundance was
greater involved apoptosis, protein phosphorylation,
reactive oxygen species metabolism, and microtubule/
cytoskeleton function. Results for manually curated sets
comprising complexes I–V of the respiratory chain are
shown in Fig. 5. Compared with lean control subjects,
complex I, III, IV, and V proteins showed a graded
decrease from lean to obese nondiabetic subjects to
patients with type 2 diabetes. Differences in complexes
III and IV achieved statistical significance (P  0.05).
The program GEDI was used to visualize groups of
proteins that had similar relative protein abundance dif-
ferences compared with a global median value (Fig. 6).
This analysis showed seven major regions with similar
patterns of protein abundance among the three groups.
Areas 3 and 5 contain many mitochondrial oxidative
phosphorylation proteins (lower in insulin resistance),
whereas areas 1 and 2 contain a number of proteins
involved in protein degradation (higher in insulin resis-
tance). A list of proteins in the numbered regions is given
in supplemental Table 5.
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FIG. 4. Relative changes in abundance in mitochondrial proteins (A), cytoskeletal and structural proteins (B), TCP1 (chaperonin) complex
proteins (C), and proteins involved in proteolytic process or protein modification leading to degradation (D). Data are given as means SE NSAF
values for lean control (), obese nondiabetic (u), and type 2 diabetic participants (f). All NSAF values were multiplied by 10,000 for purposes
of presentation. *P < 0.05, **P < 0.01 vs. lean control subjects (see RESEARCH DESIGN AND METHODS for details). All proteins shown were different
among groups by ANOVA (at least P < 0.05) or differed by at least a factor of 2 among at least two groups. Numbers in parentheses as follows
indicate the number of subjects with that protein assigned (non–zero-NSAF) for lean, obese, and diabetic subjects, respectively: COX6C,
cytochrome c oxidase subunit 6c (7, 8, 7); UQCRQ, ubiquinol-cytochrome C reductase complex ubiquinone-binding protein QP-C (6, 2 ,4);
CHCHD3, coiled-coil helix coiled-coil helix domain containing protein 3 (8, 7, 4); TCP1, T-complex protein 1 delta (7, 7, 8), theta (7, 7, 8), alpha
(6, 6, 7), eta (2, 4, 6); Beta 3, proteasome subunit beta type 3 (4, 4, 6); Alpha 2, proteasome subunit alpha type 2 (4, 8, 7); 26S reg. 3, 26S
proteasome regulatory subunit 3 (4, 3, 6); 26S reg. 4, 26S proteasome regulatory subunit 4 (3, 6, 4); Beta 4, proteasome subunit beta type 4 (4,
6, 6); 26S sub. 11, 26S proteasome subunit 11 (4, 6, 7); 26S reg. 7, 26S regulatory subunit 7 (5, 5, 7).
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FIG. 5. Results of analysis of manually curated protein sets for
complexes I–V of the electron transport chain (ETC). Data are given as
means  SE scaled NSAF values for lean control (), obese nondia-
betic (u), and type 2 diabetic participants (f). *P< 0.05, **P< 0.01 vs.
lean control subjects (see RESEARCH DESIGN AND METHODS for details).
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Proteins differing in abundance between diabetic and
obese nondiabetic subjects. To gain insight into alter-
ations in protein abundance due to diabetic status, we
examined proteins that differed by a factor of 2 between
the diabetic and obese groups. Proteins involved in mito-
chondrial function in general were lower in the diabetic
group than in the obese nondiabetic subjects. HSP90
co-chaperone CDC37 and NG,NG-dimethylarginine dimeth-
ylaminohydrolase-1 were lower in diabetic versus obese
subjects, but still greater in abundance relative to lean
control individuals.
Immunoblot analysis of desmin and alpha actinin-2.
We performed immunoblots for desmin and alpha acti-
nin-2 protein abundance using the remaining lysate from
seven of the eight subjects in each of the three groups of
lean, obese, and diabetic volunteers. Results from densi-
tometry analysis of these proteins were expressed relative
to the 78-kDa protein PDLIM6, which was found not to
differ among the groups in abundance in the mass spec-
trometry analysis (P  0.44, protein assigned in all sub-
jects in all three groups; supplemental Table 1) or
immunoblot analysis. The results from quantification of
these blots mirrored the results using our NSAF method
and statistical analysis (Fig. 7). The correlation coefficients
between NSAF values and blot values were 0.80 (P 
0.0001) and 0.69 (P  0.001) for alpha actinin-2 and
desmin, respectively.
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FIG. 6. Heat maps clustering proteins into groups with similar abundance relative to a global median, obtained using the program GEDI. A
total of 400 proteins with spectra obtained in at least 12 of 24 subjects were analyzed. Proteins assigned by the GEDI algorithm to areas
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FIG. 7. Immunoblot analysis comparing abundance of desmin (A) and
alpha actinin-2 (B) content in skeletal muscle biopsies from lean (),
obese nondiabetic (u), and type 2 diabetic (f) (n  7 each). Density
values from blots were expressed relative to PDLIM6 protein deter-
mined on the same blots and were normalized for each protein to the
mean value of the lean controls, expressed as 100%. Representative
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in the inset for both proteins. Data are shown as means SE. *P< 0.05
vs. lean control values.
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DISCUSSION
A wide array of abnormalities is associated with skeletal
muscle insulin resistance (3–6,8,9). Because investigations
of these effects often have focused on a particular protein
or biochemical pathway, it has been problematic to dis-
cern larger patterns of differences between insulin-resis-
tant and healthy muscle. A more global approach can be
useful for identifying novel patterns of changes and lead to
new focused hypotheses. Global analyses of mRNA ex-
pression in insulin-resistant muscle by microarray analysis
revealed a pattern of reduced expression of genes involved
in mitochondrial function and metabolism (7–9). These
results helped to define mitochondrial dysfunction as a
characteristic of insulin resistance. However, mRNA ex-
pression levels may not reflect protein abundance, provid-
ing a compelling reason for a global analysis of protein
abundance changes in insulin-resistant muscle. Therefore,
the present study was undertaken to provide data that
would serve to generate new hypotheses regarding insulin
resistance. To accomplish this, we used one-dimensional
SDS-PAGE gels as the first dimension of separation in a
multi-dimension, mass spectrometry–based process for
protein assignment, with quantification using the NSAF
method (21–23).
Previous studies of mRNA expression levels revealed a
pattern of decreased expression of nuclear-encoded genes
coding for proteins involved in mitochondrial function in
insulin-resistant muscle (7–9). The present results extend
this to show that the abundance of proteins involved in
many mitochondrial functions also is reduced. Lending
further evidence for a generalized decrease in mitochon-
drial protein abundance were results of analysis of protein
sets grouped by GO classification. Of the 15 GO sets that
were significantly reduced in insulin-resistant subjects, 13
represented mitochondrial proteins. When electron trans-
port chain complex components were curated into indi-
vidual sets representing subunits of complexes I–V, all but
complex II proteins were reduced in insulin-resistant
subjects, with complexes III and IV achieving statistical
significance (P  0.05) and complex I being marginally
significant (P  0.066). These results provide confirmation
of the reports of decreased number or size of mitochon-
dria in skeletal muscle from insulin-resistant subjects
(29,30). Based on the current findings, those results can be
extended to conclude that there is a widespread decrease
in mitochondrial proteins, including components of the
respiratory chain and protein import machinery.
Results from the present studies also show changes in
abundance of several proteins involved in structure or
function of the cytoskeleton. A significantly lower abun-
dance was found of the actin capping and Z-disk compo-
nent protein alpha actinin-2. Myozenin-1, which binds to
alpha actinin (31), also was lower in abundance, as was a
major intermediate filament component, desmin. On the
other hand, a set of microtubule-related proteins, includ-
ing tubulins and kinesins, was significantly increased in
insulin resistance. Previous results have shown the essen-
tial nature of interactions of mitochondria with the cy-
toskeleton for normal mitochondrial function (32–34). It is
tempting to speculate that a relationship exists between
altered mitochondrial function and protein abundance and
abnormalities in the abundance of cytoskeletal elements,
particularly intermediate filament and Z-disk components,
in insulin-resistant muscle. Intermediate filaments in skel-
etal muscle integrate force transduction between the
sarcomere and extracellular matrix, through proteins such
as integrins and the dystroglycan complex (35,36). More-
over, intermediate filaments organize organelles in skele-
tal muscle, including mitochondria, and are involved in
regulating their function (35). We previously showed in-
flammatory-like extracellular matrix changes in insulin-
resistant muscle (37–39). The present results provide the
basis for a new hypothesis regarding the mechanisms of
insulin resistance in muscle, namely, that changes in the
extracellular matrix might lead to altered mitochondrial
function by means of altered mechano-signal transduction
produced by changes in intermediate filament protein
abundance. A scenario connecting the extracellular matrix
and mitochondrial function has been described for Beth-
lem muscular dystrophy, a collagen 6 mutation in humans
(40). This hypothesis must be tested in further studies.
Another novel change observed in the present study is
the increase in abundance of chaperonin proteins, namely
T-complex proteins (TCP-1) and HSP90 co-chaperone
CDC37. TCP-1 is a mammalian cytosolic chaperonin re-
quired for proper folding of proteins involved in cytoskel-
etal formation and contractile activity (41,42). Eight of the
10 subunits of TCP-1 were assigned in this study. Of these,
two (TCP-1  and 
) were significantly increased in one or
both groups of insulin-resistant subjects, and two others,
TCP-1  and , were increased by at least twofold in one
of the insulin-resistant groups, but were not significant by
ANOVA. The expression of TCP-1 subunits 
 and  is
under coordinated control of extracellular signal-regulated
kinase (ERK)-1/2 signaling (41), and a number of TCP-1
subunits have coordinately regulated expression (42).
These findings are consistent with reports that MAP ki-
nase/ERK signaling is preserved or increased in insulin-
resistant skeletal muscle (3,4). In insulin resistance,
plasma insulin concentrations are increased as a compen-
satory effort to normalize glucose metabolism. Because
ERK signaling is preserved or increased in insulin-resistant
muscle, in the setting of hyperinsulinemia, ERK signaling
is likely to be increased. The present finding of a coordi-
nated increase in TCP-1 abundance is the first reported
potential consequence of the increase in ERK signaling in
insulin-resistant muscle. The increased abundance of the
major cytosolic chaperonin complex TCP-1 may be related
mechanistically to the increases in abundance of several
cytoskeletal and structural proteins also found in this
study.
Another protein that showed an increase in abundance
in insulin-resistant muscle was NG,NG-dimethylarginine
dimethylaminohydrolase-1. The function of this enzyme is
to metabolize NG,NG-dimethylarginine, also called asym-
metric arginine, or ADMA (43). ADMA is a naturally
occurring inhibitor of NO synthase (44) and is increased in
plasma of individuals with hypercholesterolemia, hyper-
tension, and type 2 diabetes (45–47). The increase in
abundance of NG,NG-dimethylarginine dimethylaminohy-
drolase-1 in insulin-resistant muscle suggests that there
may be a compensatory response in muscle in an effort to
reduce ADMA.
The present findings also show that there are increases
in the abundance of a number of proteins involved in
proteasome function in insulin-resistant muscle. Although
poorly controlled diabetic subjects are characterized by
increased rates of proteolysis (48), it is less clear that a
general increase in protein turnover characterizes insulin-
resistant muscle, although some conditions associated
with insulin resistance are also associated with increased
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protein degradation, such as aging or type 1 diabetes
(49,50). On a molecular level of analysis, Wang et al. (51),
using insulin-resistant mice, showed that increased protea-
some activity could be attributed to decreased signaling
through IRS-1 and Akt, which occurs in insulin-resistant
human muscle (3,4).
It should be noted that the diabetic subjects were on
average 11 years older than the lean control subjects,
although they were not significantly older than the obese
nondiabetic subjects. All participants were middle-aged
and very sedentary, suggesting that there are no age-
related differences in physical activity. Moreover, gene
expression studies over the age range of 20 to 80 years
show few changes, and those who were observed had a
very slow rate of change over age (52). Another major
caveat of the results of this study is that not all proteins
were assigned in each subject in each group. Given this
caveat, and the limitations of statistical analysis of large
datasets where some assumptions of statistical tests em-
ployed may not be met in every case, it must be stressed
that the results from this study should serve as a starting
point for additional, more focused studies designed to test
hypotheses that might be generated by these findings.
In summary, the current results suggest that there is a
wide array of changes in protein abundance in insulin-
resistant skeletal muscle. Several potential themes emerge
that must be addressed in future studies. These themes
include lower abundance of mitochondrial proteins, alter-
ations in abundance of proteins involved in cytoskeletal
structure and function, and higher abundance of protea-
some subunits and molecular chaperones. These changes
provide new information about potential relationships
among various pathways that may converge to create
insulin resistance.
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